F-1/A: Psyence Biomedical Registers 50M Shares for Resale

Psyence Biomedical Ltd. filed an F-1/A registration statement for the potential resale of 50 million common shares by White Lion Capital, an amount vastly exceeding current outstanding shares.

Summary

• Psyence Biomedical Ltd. (PBM) is a life science biotechnology company developing natural psilocybin and ibogaine products for psychological trauma in palliative care.
• The company is registering 50,000,000 common shares for potential resale by White Lion Capital, LLC, which represents a significant percentage of outstanding shares.
• PBM has an existing equity line of credit (ELOC) with White Lion for up to $25 million, of which $14,026,983 has been utilized, leaving up to $10,973,107 available.
• PBM's lead product candidate, PEX010 (25mg natural psilocybin capsule), is in a Phase IIb clinical trial in Australia for Adjustment Disorder (AjD) due to cancer, with enrollment expected in the second half of 2025.
• The estimated cost for the 87-patient Phase IIb study is $4,500,000, with $2,444,062 already spent on a previous CRO.
• PBM reported a net income of $1,011,790 for the year ended March 31, 2025, a significant improvement from a $51,159,048 net loss in the prior year, primarily driven by fair value gains on convertible notes and warrant liabilities.
• Cash and cash equivalents increased to $6,135,166 as of March 31, 2025, from $733,188 in the prior year, with working capital turning positive at $5,965,908.
• The company implemented two reverse stock splits: 75-to-1 on November 26, 2024, and 1-for-7.97 on May 5, 2025, to regain Nasdaq compliance.
• PBM has secured new licensing and supply agreements for additional APIs, including an exclusive IP licensing agreement with PsyLabs for psilocybin in SUD/AUD and a right of first refusal for ibogaine supply.

Sentiment

Score: 6

Explanation: The company shows significant financial improvement with a net profit and positive working capital, driven by non-operating gains and successful Nasdaq compliance. Clinical trials are progressing, and new IP agreements diversify the pipeline. However, substantial future funding is required, the share offering by White Lion poses dilution risk, and R&D slowdowns indicate potential operational challenges. The out-of-the-money warrants also reflect a significant gap in market valuation.

Positives

• Achieved a net income of $1,011,790 for the year ended March 31, 2025, a substantial turnaround from a significant loss in the prior year.
• Significantly improved liquidity with cash and cash equivalents increasing to $6,135,166 and positive working capital of $5,965,908 as of March 31, 2025.
• Successfully regained compliance with Nasdaq listing requirements after implementing reverse stock splits and transferring to the Nasdaq Capital Market.
• Phase IIb clinical trial for PEX010 in Australia is progressing, with all ethics approvals received and enrollment expected to commence in the second half of 2025.
• The Australian R&D tax incentive program offers up to a 43.5% rebate on R&D expenses, making the Australian clinical trial a cost-effective endeavor.
• Secured new exclusive IP licensing and supply agreements with PsyLabs for pharmaceutical-grade psilocybin for Substance Use Disorders (SUDs) and a right of first refusal for ibogaine, diversifying the product pipeline.
• Management team possesses extensive experience (close to 60 years combined) in pharmaceutical R&D and commercialization.
• PEX010 has received regulatory approval for Phase I and II clinical trials in multiple jurisdictions (FDA, Health Canada, MHRA, EMA, TGA) and has been administered to 132 patients via Health Canada's Special Access Program with no serious adverse events reported.

Negatives

• The offering of 50,000,000 common shares by the Selling Securityholder represents vastly more than the number of outstanding shares, which could depress the market price and impair the company's ability to raise future capital.
• Despite the net income, the company has a history of significant losses and expects to incur substantial losses for the foreseeable future, with no revenue generated to date.
• The net income for 2025 was primarily driven by non-operating fair value gains on convertible notes and warrant liabilities, rather than core business operations.
• R&D expenses decreased in 2025 due to a temporary slowdown in trial activity during the transition to a new CRO, indicating potential delays in development.
• The company will require substantial additional funding to achieve its business goals, including completing Phase III trials and commercialization, and there is no guarantee that financing will be available on acceptable terms.
• Reliance on licensed intellectual property (PEX010 license from Filament expires April 2027 for Phase IIb only) and the need to secure alternative suppliers for Phase III and commercialization introduces uncertainty.
• All current warrants are significantly out-of-the-money, making their exercise unlikely in the near future and indicating a substantial gap between current share price and historical exercise prices.
• The FDA may not accept data from clinical trials conducted outside the United States, potentially requiring additional costly and time-consuming trials for US approval.

Risks

• Incurred significant losses since inception and anticipates significant losses for the foreseeable future, with no products approved for commercial sale and no revenue generated to date.
• Limited operating history makes it difficult to predict future performance, with operating results expected to fluctuate significantly.
• Requires substantial additional funding to achieve business goals; inability to obtain funding could delay, limit, or terminate product development efforts.
• The psychedelic therapy and biotechnology industries are rapidly growing and competitive, with larger competitors having greater resources.
• Current and future preclinical and clinical studies will be conducted outside the United States, and the FDA may not accept data from such studies to support NDAs.
• High rate of failure for product candidates in clinical trials; positive results from earlier trials are not necessarily predictive of future results.
• Negative results from clinical trials of others or adverse safety events involving psychedelic analogs could materially affect the business.
• Supply chain interruptions, particularly dependence on Filament for PEX010, could delay product development timelines.
• Reliance on third parties (CROs) to conduct clinical trials; failure to properly carry out duties or meet deadlines could delay regulatory approval.
• Dependence on licensed intellectual property; loss of rights to PEX010 or inability to secure alternative licenses for Phase III could severely impact the business.
• Difficulties in patient enrollment in clinical trials could delay or adversely affect clinical development activities.
• Failure to comply with healthcare regulations could lead to substantial enforcement actions, civil and criminal penalties.
• Clinical trials are expensive, time-consuming, uncertain, and susceptible to change, delay, or termination, with results open to differing interpretations.
• Serious adverse events or other safety risks could require abandonment of development, delay approval, limit market acceptance, or cause product recalls.
• Voluntary suspension or termination of a clinical trial due to unacceptable risk, unlikely regulatory approval, or insufficient funds.
• Success of product candidates is subject to constantly-evolving state and federal laws, regulations, and enforcement policies pertaining to psilocybin-containing products.
• May seek fast track or breakthrough therapy designations, but receipt is not guaranteed and does not assure faster development or approval.
• The psychedelic therapy industry and market are relatively new and may not continue to exist or grow as anticipated, with negative public opinion potentially impacting growth.
• May not be able to adequately protect or enforce intellectual property rights, especially for naturally occurring substances like psilocybin, which cannot be patented directly.
• Risk of infringing intellectual property rights of others, leading to costly lawsuits, delays, or inability to commercialize products.
• Inability to adequately prevent disclosure of trade secrets and other proprietary information could diminish product value.
• Sales of shares by the Selling Securityholder, or the perception of such sales, could depress the market price of common shares and impair ability to raise capital.
• Failure to meet applicable continued listing requirements could lead to Nasdaq delisting, reducing liquidity and market price.
• Market price and trading volume of common shares may be volatile and could decline significantly.
• Warrants are exercisable for common shares, which would increase shares eligible for future resale and result in dilution.
• Requirements of being a public company may strain resources, divert management attention, and affect ability to attract and retain qualified board members.
• Qualifies as a foreign private issuer and emerging growth company, leading to reduced SEC reporting requirements, which may make shares less attractive to investors.
• Reports financial results under IFRS, which differs from U.S. GAAP, potentially making comparisons difficult.
• U.S. taxpayers owning common shares may face adverse U.S. federal income tax consequences if classified as a Passive Foreign Investment Company (PFIC).
• Difficulties in protecting interests through U.S. courts due to Canadian incorporation and majority of operations/management outside the U.S.
• Canadian corporate governance provisions may delay or prevent a change in control.
• Does not expect to pay dividends in the foreseeable future, relying on retained earnings for business development.

Future Outlook

The company expects R&D expenditure to increase in future periods as the new CRO advances the clinical trial. General and administrative costs are also expected to remain elevated due to operating as a U.S.-listed public company. The company anticipates requiring substantial additional capital to fund Phase III trials, commercialization, and expansion into new indications like Alcohol Use Disorder (AUD) and Substance Use Disorder (SUD). There is no guarantee that the FDA will accept data from trials conducted outside the United States for direct progression to Phase III in the US.

Management Comments

• Management believes that the U.S. dollar is the currency of the primary economic environment in which it operates.
• Management believes the competitive landscape analysis of other commercial psychedelic-assisted treatments in clinical trials strongly suggests that Psyence's clinical asset has a first-mover advantage in both the palliative care and cancer-related AjD market upon approval.
• Management believes that the risk of suicide and other adverse events in clinical trials will be reduced by thorough screening, exclusion of high-risk patients, and regular monitoring.
• Management believes that it is likely there will be demand for both naturally derived psilocybin formulations as well as synthetic psilocybin (and derivatives) due to increasing demand in psilocybin-based research and patient accessibility.

Industry Context

The psychedelic therapy and biotechnology industries are experiencing rapid growth and substantial change, leading to increased competition and strategic alliances. Psyence Biomedical aims for a first-mover advantage in the palliative care and cancer-related Adjustment Disorder (AjD) market, as there are currently no FDA-approved pharmaceutical agents for AjD in this context. The industry faces challenges related to the controlled substance status of psychedelics, requiring significant efforts to build brand awareness and overcome negative public perception. Regulatory frameworks are evolving, with initiatives like the Breakthrough Therapies Act and the PACT Caucus indicating growing governmental interest in therapeutic psychedelics.

Comparison to Industry Standards

• The company's lead product candidate, PEX010, is being evaluated in a Phase IIb double-blind, randomized, placebo-controlled clinical trial, which aligns with standard rigorous clinical development practices in the biotechnology industry.
• The use of the HAM-A scale as the primary endpoint in the Phase IIb study is an FDA-validated endpoint, indicating adherence to recognized regulatory standards for efficacy measurement.
• The company's strategy to outsource clinical trial execution to a Contract Research Organization (CRO) like Southern Star Research is a common capital-efficient approach in the biotechnology industry, avoiding the overhead of in-house resources.
• The decision to pursue the Phase IIb study in Australia to benefit from the Australian Federal Government's R&D tax incentive (up to 43.5% rebate) demonstrates a strategic approach to cost-effectiveness, which is a key consideration for clinical-stage biotech companies.
• The company's focus on natural psilocybin and the exploration of the 'entourage effect' differentiates its approach from synthetic psilocybin developers, potentially offering a unique value proposition in the evolving psychedelic therapy market.
• The administration of PEX010 to real-world patients via the Health Canada Special Access Program (SAP) with no serious adverse events reported, while not a clinical trial, provides real-world safety data that can be a positive indicator compared to other emerging therapies.
• The company's historical financial performance, with significant losses and reliance on equity financing, is typical for clinical-stage biotechnology companies that have not yet commercialized products.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently aware of any pending or threatened litigation or proceeding involving any of its directors, officers, employees, or agents in which indemnification would be required or permitted.

Related Party Transactions

• On August 15, 2025, the company invested $3,500,000 in PsyLabs Ltd. by subscribing for 1,750 shares at $2,000 per share.
• On April 15, 2025, the company invested an additional $500,000 in PsyLabs Ltd. by subscribing for 250 shares at $2,000 per share.
• Certain company executives (Executive Chairman, CFO, General Counsel, and an independent director) provide consulting services to PsyLabs and, along with the CEO, collectively own less than 5% of PsyLabs' outstanding shares.
• On September 17, 2024, the company acquired 1,000 ordinary shares of PsyLabs from Psyence Group Inc. (PGI) in exchange for 35,594 common shares of the company, valued at $722,033.
• On September 3, 2024, the company entered into an exclusive, royalty-bearing IP licensing agreement with PsyLabs UK for pharmaceutical-grade psilocybin for alcohol use disorder (AUD) and substance use disorder (SUD).
• The company secured an exclusive right of first refusal for the worldwide supply of nature-derived ibogaine from PsyLabs in parallel with the April 2025 investment.
• On January 25, 2024, the company issued unsecured convertible promissory notes to PGI ($1,610,657 principal) and NCAC Sponsor ($1,615,501 principal), which were fully extinguished by December 2024 through debt-for-equity exchanges, resulting in fair value gains for the company.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution due to the resale of 50,000,000 common shares by White Lion Capital, which could depress the market price. Existing shareholders experienced dilution from previous reverse stock splits and equity financings. The out-of-the-money warrants mean current warrant holders are unlikely to exercise, limiting immediate dilution from that source but also indicating a low current share price relative to historical exercise prices. Improved financial position (net income, positive working capital) could be positive for investor confidence, but the reliance on non-operating gains and future capital raises remains a concern.
• **Employees/Consultants:** The 2023 Equity Incentive Plan provides equity ownership opportunities to attract, retain, and motivate employees and consultants, aligning their interests with shareholders. Management changes and new appointments following the Business Combination aim to strengthen leadership.
• **Customers/Patients:** The development of natural psilocybin and ibogaine products for psychological trauma in palliative care, AUD, and SUD aims to address significant unmet medical needs, potentially offering new therapeutic options and improving quality of life for patients.
• **Suppliers/Partners:** Dependence on third-party suppliers like Filament for PEX010 and new suppliers for Phase III, as well as CROs like Southern Star Research, highlights the importance of these relationships for clinical development and future commercialization. New licensing agreements with PsyLabs strengthen the supply chain for future product candidates.
• **Creditors:** The full extinguishment of convertible and promissory notes in 2025 reduces debt liabilities, improving the company's balance sheet and potentially its creditworthiness.

Next Steps

• Commence enrollment for the Phase IIb clinical trial in Australia in the second half of 2025.
• Advance the Phase IIb clinical trial towards its next development milestones, expecting increased R&D expenditure.
• Prepare for an end of Phase II meeting with the FDA after the completion of the Phase IIb Study.
• Potentially proceed directly to a Phase III trial in the United States, subject to FDA review and IND opening, if Phase IIb results are positive.
• Engage alternative suppliers for drug product for pivotal Phase III studies and future studies in other indications, following the conclusion of the Phase IIb Study.
• Continue to evaluate the bridging program into Phase III, which will require regulatory agency approval.
• Expand targeted indications beyond cancer-related AjD to address different types of AjD and other secondary indications, both in palliative and non-palliative contexts.
• Initiate the creation of a steering committee and conduct preliminary market research for a planned Alcohol Use Disorder (AUD) study.
• Monitor the evolution of Australia's regulations pertaining to psilocybin and clinical trials.
• Continue to operate within a U.S. public company environment, expecting elevated general and administrative costs and professional fees.

Key Dates

Recommendation

The company has shown significant financial improvement, moving from a substantial loss to a net income and achieving positive working capital. This, coupled with successful Nasdaq compliance and ongoing clinical trials in a high-potential market (psychedelic therapies for mental health), presents a positive operational trajectory. However, the net income is largely driven by non-operating fair value adjustments, not core revenue, and the company still requires substantial future funding. The registration of 50 million shares for resale by White Lion Capital, an amount vastly exceeding current outstanding shares, poses a significant dilution risk that could depress the stock price. While the long-term potential in the psychedelic therapy market is attractive, the immediate dilution risk and the need for further capital raises suggest a 'hold' position until more clarity emerges on the commercialization pathway and the impact of the share resale.

Keywords

Psyence Biomedical, PBM, Psilocybin, Ibogaine, Psychedelic Therapy, Palliative Care, Adjustment Disorder, Clinical Trials, Biotechnology, SEC Filing, F-1/A, White Lion Capital, Equity Line of Credit, Reverse Stock Split, Nasdaq, Drug Development, Mental Health, SUD, AUD, PEX010, Filament Health, PsyLabs